Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 4/20 | 0.36 |
| ▸ | CCR2 | P41597 | 7/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5076804 | 0.85 | ACP3 (0.43) | IDO1SLC6A4 | |
| SCHEMBL5274756 | 0.68 | IDO1 (0.47) | TACR1TSHRIDO1CYP2D6CYP3A4 | |
| SCHEMBL568587 | 0.68 | RHOC (0.46) | TACR1MTORIDO1 | |
| Hydrochloric Acid SCHEMBL3152128 | 0.67 | RHOC (0.45) | TACR1MTORIDO1 | |
| Hydrochloric Acid SCHEMBL3143818 | 0.67 | RHOC (0.45) | TACR1MTORIDO1 | |
| SCHEMBL1295656 | 0.67 | IDO1 (0.48) | TACR1MTORIDO1 | |
| SCHEMBL3400670 | 0.66 | TACR1 (0.46) | TACR1MTORIDO1 | |
| SCHEMBL15168718 | 0.66 | TACR1 (0.41) | TACR1TSHRMTORIDO1CYP2D6 | |
| SCHEMBL5275909 | 0.66 | HSD11B1 (0.43) | TACR1TSHRMTORIDO1CYP2D6 | |
| SCHEMBL5082479 | 0.66 | LMNA (0.39) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060235056-A1 | Novel 3,4-disubstituted 1,2,3,6-tetrahydropyridine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-10-19 | — | — | US | disclosed |
| EP-1620403-A1 | NOVEL 3,4-DISUBSTITUTED 1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004096769-A1 | NOVEL 3,4-DISUBSTITUTED 1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235056-A1 | Novel 3,4-disubstituted 1,2,3,6-tetrahydropyridine derivatives | REN, ACE, ACE2 | TACR1 145/4885CCR2 2506/4885TSHR 4364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.